1,2,4-Benzenetricarboxylic acid 1,2-anhydride
RTECS #
DC2050000
CAS #
Updated
December 2018
Molecular Weight
192.13
Molecular Formula
C9H4O5
Synonyms
1,2,4-Benzenetricarboxylic acid anhydride
1,2,4-Benzenetricarboxylic acid, cyclic 1,2-anhydride
1,2,4-Benzenetricarboxylic anhydride
1,3-Dihydro-1,3-dioxo-5-isobenzofurancarboxylic acid
1,3-Dioxo-5-phthalancarboxylic acid
4-Carboxyphthalic anhydride
5-Phthalanacarboxylic acid, 1,3-dioxo-
Anhydrotrimellic acid
Diphenylmethane-4,4'-diisocyanate-trimellic anhydride-ethomid HT polymer
Epon 9150
NCI-C56633
Trimellic acid 1,2-anhydride
Trimellic acid anhydride
Trimellitic acid cyclic 1,2-anhydride
Trimellitic anhydride
Trimellitic anhydride (ACGIH)
1,2,4-Benzenetricarboxylic acid, cyclic 1,2-anhydride
1,2,4-Benzenetricarboxylic anhydride
1,3-Dihydro-1,3-dioxo-5-isobenzofurancarboxylic acid
1,3-Dioxo-5-phthalancarboxylic acid
4-Carboxyphthalic anhydride
5-Phthalanacarboxylic acid, 1,3-dioxo-
Anhydrotrimellic acid
Diphenylmethane-4,4'-diisocyanate-trimellic anhydride-ethomid HT polymer
Epon 9150
NCI-C56633
Trimellic acid 1,2-anhydride
Trimellic acid anhydride
Trimellitic acid cyclic 1,2-anhydride
Trimellitic anhydride
Trimellitic anhydride (ACGIH)
Skin and Eye Irritation and References
Route/Organism | Dose | Effect | Reference |
---|---|---|---|
skin /mouse | 10%/3D- intermittent | TOLED5 136,121,2002 |
Acute Toxicity Data and References
Route/Organism | Dose | Effect | Reference |
---|---|---|---|
In Vitro/Human, leukemia cells | Inhibitor Concentration (50 percent kill): 81.2 mg/L/24H | In Vitro Toxicity Studies: Other assays | TIVIEQ 26,1150,2012 |
In Vitro/Human, leukemia cells | Inhibitor Concentration Low: >1000 µmol/L | In Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc. | TOLED5 239,32,2015 |
In Vitro/Human, leukemia cells | Inhibitor Concentration (50 percent kill): 26900 µmol/L/24H | In Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc. | TOLED5 239,32,2015 |
In Vitro/Human, leukemia cells | Inhibitor Concentration Low: 1000 µmol/L | In Vitro Toxicity Studies: Other assays | TOLED5 239,32,2015 |
In Vitro/Human, lung | Inhibitor Concentration Low: 3.03 µg/well/24H | In Vitro Toxicity Studies: Other assays | TIVIEQ 27,1151,2013 |
In Vitro/Human, lung | Inhibitor Concentration (20 percent kill): 2.73 mmol/L | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 30,274,2015 |
In Vitro/Human, lung | Inhibitor Concentration (50 percent kill): 6.7 gm/L/3H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 27,174,2013 |
In Vitro/Human, lung | Inhibitor Concentration (50 percent kill): 33 gm/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 27,174,2013 |
In Vitro/Human, lung | Inhibitor Concentration (50 percent kill): 23 gm/L/24H | In Vitro Toxicity Studies: Other assays | TIVIEQ 27,174,2013 |
In Vitro/Human, lung tumor | Inhibitor Concentration (50 percent kill): 2.7 gm/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 27,174,2013 |
In Vitro/Human, skin | Inhibitor Concentration Low: 1 pph/15M | In Vitro Toxicity Studies: Other assays | TIVIEQ 29,787,2015 |
In Vitro/Mouse, fibroblast | Inhibitor Concentration (50 percent kill): 2.4 gm/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 27,174,2013 |
In Vitro/Rat, lung | Inhibitor Concentration (50 percent kill): 14.4 mmol/L/1H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 32,347,2016 |
In Vitro/Rat, lung | Inhibitor Concentration (50 percent kill): 11.5 mmol/L/1H | In Vitro Toxicity Studies: Cell protein synthesis | TIVIEQ 32,347,2016 |
In Vitro/Rat, lung | Inhibitor Concentration (50 percent kill): 10 mmol/L/1H | Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | TIVIEQ 32,347,2016 |
inhalation/mouse | lowest published toxic concentration: 25 pph/4H | Immunological Including Allergic: Increase in cellular immune response | TOXID9 66,160,2002 |
inhalation/rat | Lethal concentration: >7400 mg/m3/4H | 85INA8 6,1642,1991 | |
inhalation/rat | lowest published toxic concentration: 15 mg/m3/24H | Lung, Thorax, or Respiration: Structural or functional change in trachea or bronchi Lung, Thorax, or Respiration: Respiratory obstruction Immunological Including Allergic: Hypersensitivity delayed (multiple organ involvement) | TXAPA9 197,175,2004 |
inhalation/rat | lowest published toxic concentration: 15 mg/m3/15M | Lung, Thorax, or Respiration: Changes in lung weight Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | TOPADD 36,985,2008 |
intratracheal/guinea pig | lowest published toxic dose: 2 mg/kg | Vascular: BP lowering not characterized in autonomic section Lung, Thorax, or Respiration: Bronchiolar constriction, including asthma Immunological Including Allergic: Increase in cellular immune response | TXCYAC 178,89,2002 |
intratracheal/mouse | lowest published toxic dose: 5 mg/kg | Lung, Thorax, or Respiration: Other changes Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | TOXID9 60,173,2001 |
oral/mouse | lethal dose (50 percent kill): 1900 mg/kg | Lung, Thorax, or Respiration: Dyspnea | GTPZAB 18(7),57,1974 |
oral/rabbit | lethal dose (50 percent kill): 5600 mg/kg | 85INA8 6,1642,1991 | |
skin/rat | lowest published toxic dose: 100 mg/kg | Skin: After topical application: Dermatitis, allergic Immunological Including Allergic: Increase in humoral response | TOXID9 60,174,2001 |
skin/rat | lowest published toxic dose: 600 mg/kg | Lung, Thorax, or Respiration: Sputum Immunological Including Allergic: Increase in cellular immune response Immunological Including Allergic: Anaphylaxis (multiple organ involvement) | ARTODN 76,538,2002 |
Other Multiple Dose Data and References
Route/Organism | Dose | Effect | Reference |
---|---|---|---|
inhalation/mouse | lowest published toxic concentration: 30 mg/m3/3D- intermittent | Immunological Including Allergic: Increased immune response Biochemical: Metabolism (intermediary): Other proteins Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | TXCYAC 261,103,2009 |
inhalation/rat | lowest published toxic concentration: 25 mg/m3/4D- intermittent | Lung, Thorax, or Respiration: Sputum Immunological Including Allergic: Increase in cellular immune response Immunological Including Allergic: Anaphylaxis (multiple organ involvement) | ARTODN 76,538,2002 |
inhalation/rat | lowest published toxic concentration: 120 mg/m3/4D- intermittent | Lung, Thorax, or Respiration: Dyspnea Immunological Including Allergic: Increase in cellular immune response Immunological Including Allergic: Anaphylaxis (multiple organ involvement) | ARTODN 76,538,2002 |
inhalation/rat | lowest published toxic concentration: 258 µg/m3/6H/10D- intermittent | Lung, Thorax, or Respiration: Fibrosis, focal (pneumoconiosis) Lung, Thorax, or Respiration: Other changes Lung, Thorax, or Respiration: Changes in lung weight | TXAPA9 87,67,1987 |
inhalation/rat | lowest published toxic concentration: 5 mg/m3/3D- intermittent | Immunological Including Allergic: Increase in humoral response Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | TXCYAC 172,157,2002 |
inhalation/rat | lowest published toxic concentration: 25 mg/m3/5D- intermittent | Lung, Thorax, or Respiration: Acute pulmonary edema Lung, Thorax, or Respiration: Changes in lung weight Immunological Including Allergic: Hypersensitivity delayed (multiple organ involvement) | TOXID9 72,230,2003 |
multiple/mouse | lowest published toxic dose: 280 mg/kg/35D- intermittent | Immunological Including Allergic: Increase in humoral response | TXCYAC 277,29,2010 |
skin/mouse | lowest published toxic dose: 50 pph/3D- intermittent | Immunological Including Allergic: Increased immune response Biochemical: Metabolism (intermediary): Other proteins Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | TXCYAC 261,103,2009 |
skin/mouse | lowest published toxic dose: 360 mg/kg/6D- intermittent | Skin: After topical application: Cutaneous sensitization (experimental) | FCTOD7 48,1704,2010 |
skin/mouse | lowest published toxic dose: 300 mg/kg/3D- intermittent | Skin: After topical application: Cutaneous sensitization (experimental) Immunological Including Allergic: Increase in cellular immune response | TXAPA9 205,259,2005 |
skin/mouse | lowest published toxic dose: 90 mg/kg/3D- continuous | Immunological Including Allergic: Increase in cellular immune response | TXCYAC 232,132,2007 |
skin/mouse | lowest published toxic dose: 18 ul/kg/3D- intermittent | Skin: After topical application: Cutaneous sensitization (experimental) | TOLED5 180,1,2008 |
skin/mouse | lowest published toxic dose: 180 ul/kg/17D- intermittent | Skin: After topical application: Cutaneous sensitization (experimental) | TOLED5 180,1,2008 |
skin/mouse | lowest published toxic dose: 182 ul/kg/31D- intermittent | Skin: After topical application: Cutaneous sensitization (experimental) Immunological Including Allergic: Increased immune response | TOLED5 180,1,2008 |
skin/mouse | lowest published toxic dose: 17 mg/kg/17D- intermittent | Immunological Including Allergic: Increase in cellular immune response Immunological Including Allergic: Increase in humoral response | TOLED5 181,163,2008 |
skin/mouse | lowest published toxic dose: 1100 mg/kg/8D- intermittent | Immunological Including Allergic: Increase in cellular immune response Biochemical: Metabolism (intermediary): Other proteins Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | TXCYAC 252,17,2008 |
skin/mouse | lowest published toxic dose: 2 mL/kg/2D- intermittent | Immunological Including Allergic: Increase in humoral response | TXCYAC 194,147,2003 |
skin/mouse | lowest published toxic dose: 600 mg/kg/3D- intermittent | Immunological Including Allergic: Increase in cellular immune response Immunological Including Allergic: Increase in humoral response | TXCYAC 206,221,2005 |
skin/mouse | lowest published toxic dose: 600 mg/kg/3D- intermittent | Skin: After topical application: Cutaneous sensitization (experimental) | TXCYAC 193,191,2003 |
skin/mouse | lowest published toxic dose: 600 mg/kg/3D- intermittent | Immunological Including Allergic: Increase in cellular immune response Immunological Including Allergic: Hypersensitivity delayed (multiple organ involvement) Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | TXCYAC 188,1,2003 |
skin/mouse | lowest published toxic dose: 1144 mg/kg/13D- intermittent | Immunological Including Allergic: Increase in cellular immune response Immunological Including Allergic: Hypersensitivity delayed (multiple organ involvement) | JJATDK 20,221,2000 |
skin/mouse | lowest published toxic dose: 7.5 mg/kg/3D- intermittent | Immunological Including Allergic: Increase in cellular immune response | JJATDK 20,221,2000 |
skin/mouse | lowest published toxic dose: 1500 mg/kg/7D- intermittent | Immunological Including Allergic: Increase in cellular immune response Immunological Including Allergic: Increase in humoral response | JJATDK 22,397,2002 |
skin/mouse | lowest published toxic dose: 300 mg/kg/3D- intermittent | Skin: After topical application: Cutaneous sensitization (experimental) Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | TXAPA9 184,46,2002 |
skin/mouse | lowest published toxic dose: 700 mg/kg/8D- intermittent | Skin: After topical application: Cutaneous sensitization (experimental) Immunological Including Allergic: Increase in cellular immune response | FCTOD7 40,1881,2002 |
skin/rat | lowest published toxic dose: 515 mg/kg/8D- intermittent | Skin: After topical application: Cutaneous sensitization (experimental) Immunological Including Allergic: Increase in cellular immune response | FCTOD7 40,1881,2002 |
skin/rat | lowest published toxic dose: 938 mg/kg/7D- intermittent | Skin: After topical application: Primary irritation Immunological Including Allergic: Other immediate (humoral): uticaria, allergic rhinitis, serum sickness (multiple organ involvement) | TXCYAC 117,229,1997 |
skin/rat | lowest published toxic dose: 468.75 mg/kg/7D- intermittent | Lung, Thorax, or Respiration: Acute pulmonary edema Lung, Thorax, or Respiration: Changes in lung weight Immunological Including Allergic: Hypersensitivity delayed (multiple organ involvement) | TOXID9 72,230,2003 |
skin/rat | lowest published toxic dose: 4.2 mg/kg/7D- intermittent | Immunological Including Allergic: Increase in humoral response Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | TXCYAC 172,157,2002 |
skin/rat | lowest published toxic dose: 16 mg/kg/21D- intermittent | Immunological Including Allergic: Hypersensitivity delayed (multiple organ involvement) | TOXID9 66,242,2002 |
skin/rat | lowest published toxic dose: 83 mg/kg/7D- intermittent | Lung, Thorax, or Respiration: Structural or functional change in trachea or bronchi Immunological Including Allergic: Increased immune response | TXCYAC 194,1,2003 |
subcutaneous/guinea pig | lowest published toxic dose: 180 mg/kg/5D- intermittent | Lung, Thorax, or Respiration: Structural or functional change in trachea or bronchi Immunological Including Allergic: Increase in cellular immune response | TXCYAC 178,89,2002 |
Reviews
Organization | Standard | Reference |
---|---|---|
American Conference of Governmental Industrial Hygienists (ACGIH) | Threshold Limit Value-time-weighted average 0.0005 mg/m3 | DTLVS* TLV/BEI,2013 |
American Conference of Governmental Industrial Hygienists (ACGIH) | Threshold Limit Value-short term exposure limit 0.002 mg/m3 (inhal,vapor,skin,sen) | DTLVS* TLV/BEI,2013 |
TOXICOLOGY REVIEW | BPCT** -,183,1974 | |
TOXICOLOGY REVIEW | TOLED5 140-141,213,2003 | |
TOXICOLOGY REVIEW | BLREV* 3,71,1989 | |
TOXICOLOGY REVIEW | FCTOD7 55,596,2013 | |
TOXICOLOGY REVIEW | RTOPDW 55,43,2009 | |
TOXICOLOGY REVIEW | RTOPDW 56,54,2010 |
Standards and Regulations
NIOSH Documentation and Surveillance
Organization | Standard | Reference |
---|---|---|
National Institute for Occupational Safety and Health (NIOSH) Recommended Exposure Level TO TRIMELLITIC ANHYDRIDE-air | 10H time-weighted average 0.005 ppm | NIOSH* DHHS #92-100,1992 |
National Occupational Exposure Survey 1983 | Hazard Code 83588; Number of Industries 9; Total Number of Facilities 358; Number of Occupations 13; Total Number of Employees Exposed 17745; Total Number of Female Employees Exposed 5236 | |
National Occupational Hazard Survey 1974 | Hazard Code 83588; Number of Industries 8; Total Number of Facilities 196; Number of Occupations 31; Total Number of Employees Exposed 11308 |
Status in Federal Agencies
Page last reviewed: November 16, 2018
Content
source: National Institute for Occupational Safety and Health